Krsnaa Diagnostics Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,635 Cr
- P/E
- 16.53
- ROE
- 10.90%
- PEG
- 0.93
- Price to sales
- 2.26
- Debt to equity
- 0.54
- 52W high / low
- ₹827 / ₹495
- Sales growth (5Y)
- 11.75%
- EBITDA margin
- 30.20%
- Net profit margin
- 14.87%
- Promoter holding
- 27.11%
- Sales (last year)
- ₹726 Cr
Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns.[1]
Guidance scorecard · Q1 FY27 call
What Krsnaa Diagnostics Ltd's management guided
and where it ranks in Healthcare Services
Healthcare Services
RevenueQ1 FY27 call
20–40%- Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially.
- Rajasthan PPP Project: Revenue expected to double in coming quarters with a full-year target of INR100-150 crores, and aspirational target of INR200-250 crores.
- Retail Business: Currently contributing around 8-9% of sales, anticipated to grow exponentially by the end of the financial year driven by new wellness and illness packages.
- New Projects: Expansion with additional PPP projects in pipeline including Himachal Pradesh and scaling up of MRI centers expected to contribute to top-line growth.
2 more points from Krsnaa Diagnostics Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
Up 0–2%See what Krsnaa Diagnostics Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- The company has raised funds via promoter infusion through warrants.
- These funds are intended for capital expenditure related to ongoing projects and certain acquisitions planned by the company.
- The infrastructure-led business model requires front-ended capital expenditure for building laboratories, installing equipment, and staffing teams before volume ramps up.
- Investments have been made in building labs, diagnostic networks, and launching new MRI centers, especially highlighted in Rajasthan and other PPP projects.
2 more points from Krsnaa Diagnostics Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
PlannedSee what Krsnaa Diagnostics Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Rajasthan project is fully operational with 31 Mother labs, 62 hub labs, and 1,228 collection centers, offering significant future revenue visibility and scale.
- Radiology expansion includes 17 MRI centers in the pipeline; 8 MRI centers in Maharashtra were inaugurated and operationalized in Q1 FY27.
- Additional PPP projects in the pipeline beyond Rajasthan are expected to materialize and serve as new growth engines.
- Retail business is expanding rapidly, with over 4,000 touchpoints across 7 states, leveraging an asset-light franchise model for growth.
2 more points from Krsnaa Diagnostics Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹903 Cr | — | |
| 2 | 40%+ | Flat | ₹583 Cr | 22.2 | |
| 3 | Aster DM Quality Care Ltd | 20–40% | Up 2%+ | ₹58,782 Cr | 162.9 |
| 4 | Krsnaa Diagnost.This stock | 20–40% | Up 0–2% | ₹1,730 Cr | 17.5 |
| 5 | 20–40% | Up 0–2% | ₹580 Cr | 11.9 | |
| 6 | 20–40% | Flat | ₹1.13L Cr | 53.9 |
Sign up free to see every company in the sector ranking and track Krsnaa Diagnostics Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingKrsnaa Diagnostics Ltd announcements
All announcements →- Fundraise / allotmentNotableKrsnaa Diagnostics receives corrected in-principle approval from BSE for warrants issue
- Fundraise / allotmentNotableKrsnaa Diagnostics gets BSE and NSE in-principle approval for 16,21,000 warrants
Financials of Krsnaa Diagnostics Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Krsnaa Diagnostics Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 116 | 132 | 147 | 152 | 159 | 163 | 179 | 165 | 175 | 176 | 183 | 159 | 173 |
| Expenses + | 91 | 100 | 116 | 113 | 116 | 120 | 126 | 117 | 121 | 126 | 125 | 112 | 116 |
| Operating Profit | 25 | 32 | 31 | 38 | 43 | 43 | 52 | 48 | 53 | 50 | 58 | 48 | 57 |
| OPM % | 22% | 24% | 21% | 25% | 27% | 26% | 29% | 29% | 31% | 29% | 32% | 30% | 33% |
| Other Income + | 6 | 4 | 4 | 4 | 4 | 7 | 5 | 9 | 4 | 4 | 4 | 4 | 31 |
| Interest | 2 | 2 | 3 | 4 | 7 | 5 | 6 | 6 | 7 | 6 | 8 | 8 | 12 |
| Depreciation | 15 | 16 | 18 | 21 | 18 | 21 | 22 | 23 | 22 | 22 | 23 | 23 | 22 |
| Profit before tax | 14 | 19 | 14 | 17 | 22 | 24 | 28 | 28 | 29 | 26 | 31 | 21 | 54 |
| Tax % | 17% | 18% | 20% | 20% | 17% | 23% | 23% | 24% | 28% | 26% | 24% | 22% | 20% |
| Net Profit + | 12 | 15 | 11 | 14 | 18 | 18 | 22 | 22 | 21 | 20 | 23 | 16 | 43 |
| EPS in Rs | 3.76 | 4.86 | 3.60 | 4.21 | 5.70 | 5.63 | 6.80 | 6.69 | 6.53 | 6.03 | 7.16 | 5.08 | 13.37 |
Financials of Krsnaa Diagnostics Ltd
Profit & Loss
Annual income statement trend
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 36 | 57 | 108 | 147 | 258 | 396 | 455 | 464 | 590 | 682 | 691 |
| Expenses + | 35 | 42 | 169 | 87 | 373 | 302 | 320 | 340 | 444 | 485 | 478 |
| Operating Profit | 0 | 15 | -62 | 60 | -114 | 94 | 135 | 124 | 146 | 197 | 213 |
| OPM % | 1% | 26% | -57% | 41% | -44% | 24% | 30% | 27% | 25% | 29% | 31% |
| Other Income + | 3 | 4 | 3 | 2 | 13 | 265 | 15 | 19 | 17 | 26 | 43 |
| Interest | 6 | 6 | 8 | 16 | 25 | 26 | 18 | 8 | 16 | 25 | 34 |
| Depreciation | 5 | 10 | 18 | 26 | 32 | 37 | 41 | 54 | 75 | 88 | 90 |
| Profit before tax | -7 | 2 | -84 | 21 | -158 | 295 | 90 | 82 | 72 | 110 | 132 |
| Tax % | 6% | 8% | -29% | 40% | -29% | 37% | 21% | 23% | 19% | 24% | 22% |
| Net Profit + | -8 | 2 | -60 | 12 | -112 | 185 | 71 | 64 | 59 | 83 | 103 |
| EPS in Rs | -15.05 | 4.01 | -116.54 | 24.15 | -216.83 | 284.73 | 22.52 | 20.23 | 18.14 | 25.65 | 31.65 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 11% | 14% | 14% | 11% | 0% |
Financials of Krsnaa Diagnostics Ltd
Balance Sheet
Capital structure and asset base
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 6 | 16 | 16 | 16 | 16 | 16 | |
| Reserves | 4 | 6 | 43 | -217 | -17 | 671 | 727 | 799 | 877 | 976 | |
| Borrowings + | 131 | 102 | 330 | 246 | 474 | 41 | 32 | 160 | 202 | 531 | |
| Other Liabilities + | 24 | 63 | 115 | 596 | 146 | 149 | 134 | 197 | 188 | 295 | |
| Total Liabilities | 163 | 176 | 493 | 630 | 609 | 877 | 909 | 1,172 | 1,283 | 1,818 | |
| Fixed Assets + | 59 | 116 | 223 | 275 | 309 | 386 | 471 | 647 | 668 | 651 | |
| CWIP | 20 | 6 | 42 | 9 | 4 | 28 | 25 | 10 | 3 | 208 | |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 58 | |
| Other Assets + | 85 | 53 | 228 | 345 | 297 | 463 | 413 | 514 | 581 | 902 | |
| Total Assets | 163 | 176 | 493 | 630 | 609 | 877 | 909 | 1,172 | 1,283 | 1,818 |
Financials of Krsnaa Diagnostics Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 59 | 61 | 38 | 119 | 129 | 75 | 24 | 89 | 134 | ||
| Cash from Investing Activity + | -53 | -201 | -77 | -67 | -241 | -109 | -129 | -102 | -391 | ||
| Cash from Financing Activity + | -37 | 145 | 6 | 20 | 176 | -33 | 84 | 14 | 278 | ||
| Net Cash Flow | -31 | 4 | -33 | 71 | 64 | -66 | -20 | 1 | 22 | ||
| Free Cash Flow | 6 | -42 | -39 | 50 | -2 | -59 | -169 | -21 | -80 | ||
| CFO/OP | 410% | 114% | -42% | 134% | 100% | 71% | 30% | 55% | 75% |
Financials of Krsnaa Diagnostics Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 91 | 140 | 87 | 69 | 48 | 59 | 110 | 152 | 163 | |
| Inventory Days | 21 | 24 | 89 | 54 | |||||||
| Days Payable | 76 | 99 | 878 | 119 | |||||||
| Cash Conversion Cycle | 32 | 15 | -650 | 87 | 69 | 48 | 59 | 110 | 152 | 98 | |
| Working Capital Days | -428 | -119 | -234 | -133 | -82 | -21 | 16 | -18 | 28 | 66 | |
| ROCE % | 7% | -65% | 129% | 18% | 12% | 10% | 13% | 13% |
Guidance history
How Krsnaa Diagnostics Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Up 0–2% | Planned | Planned | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | Planned | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | Planned | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
16 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −34.9% | 18% |
| Last 6 months | −14.4% | 31% |
| Last 3 months | −4.5% | 58% |
The price is 49.4% below its all-time high of ₹995.55 (29 Nov 2024). Stocks more than 20% below their peak have their score halved, so 31 became 16.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Krsnaa Diagnostics Ltd: 0.4 × 18 + 0.4 × 31 + 0.2 × 58 = 31, halved to 16 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Krsnaa Diagnostics Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio